Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

Why Allergy Therapeutics (LSE:AGY) Nearly Doubled Its Cash After Refinancing and a German Launch

Allergy Therapeutics plc, which trades on AIM under the code AGY, describes itself as a fully integrated commercial biotechnology company specialising in allergy immunotherapies. It sells treatments designed to modify the immune response to allergens such as pollen, and it develops next-generation products, including …

Ankur Sharma | 29 September 2026

Egetis Therapeutics wins FDA approval for Emcitate, first treatment for MCT8 deficiency

Egetis Therapeutics (LSE:0ABW), the Stockholm-headquartered rare disease company with operations in the US and Europe, announced on 28 September 2026 that the FDA has approved EMCITATE (tiratricol). The approved indication is the treatment of peripheral thyrotoxicosis in adult and paediatric patients with monocarboxylate transporter …

Ankur Sharma | 29 September 2026

Why Futura Medical (LSE:FUM) Raised Fresh Equity and Launched a Formal Sale Process for Its Eroxon Portfolio

On 3 September 2026, Futura announced a placing, subscription and retail offer at 0.2 pence per share, alongside the launch of a formal sale process and M&A process under theTakeoverCode, which began an offer period. The company said the current market valuation does not …

Ankur Sharma | 28 September 2026

Why Did Convatec Group Plc LSE:CTEC Rise 0.86% Amid a Firmer Tone Across London-Listed Medical Products Shares?

Convatec Group Plc — LSE:CTEC closed 0.86% higher on28 September 2026, with the shares at 211.20p after a gain of 1.80p on the day.

Ishan Mudgal | 28 September 2026

Why Did Smith & Nephew Plc LSE:SN Rise 0.89% Amid a Firmer Tone Across London-Listed Medical Technology Shares?

Smith & Nephew Plc — LSE:SN closed 0.89% higher on28 September 2026, with the shares at 1,017.00p after a gain of 9.00p on the day.

Ishan Mudgal | 28 September 2026

Why NIOX Group (LSE:NIOX) Plans to Return Excess Capital After Its First-Half Trading Update

NIOX Group describes itself as a medical device company specialising in point-of-care FeNO testing, used in the diagnosis and management of asthma and COPD. FeNO, or fractional exhaled nitric oxide, is measured from a patient's breath, and the group's NIOX devices are designed for …

Ankur Sharma | 28 September 2026

Oxford Nanopore Sequences a Recovery: Is the Path to Breakeven Finally in View?

Oxford Nanopore Technologies PLC shares rose 2.48% today to 186.10p, up 4.50p, according to the market data provided.

Divya Sood | 28 September 2026

CVS Group Bounces Back: Has CMA Clarity Given the Vet Chain a Clean Bill of Health?

The move appears to be apartial reboundafter the shares fell around 5% following the company's full-year results on 24 September. There does not appear to be a new company-specific announcement today, and the gain comes alongside a firmer session for UK mid-caps.

Divya Sood | 28 September 2026

Could ImmuPharma Plc (LSE:IMM) Extend Its 15.44% Rally as P140 and Kapiglucagon Become Key Growth Catalysts?

ImmuPharma has recorded a15.44% gain on 28 September 2026, bringing renewed attention to LSE:IMM.

Ankur Sharma | 28 September 2026

Why Is MicroSalt (LSE:SALT) Stock Rising 14.29% as Investors Focus on Funding, Growth and Its Next Commercial Milestones? (LSE:SALT)

MicroSalt (LSE:SALT) has attracted renewed market attention after climbing14.29% on 28 September 2026. The move comes immediately ahead of a potentially important period for the company, with interim financial results due on 29 September and the current retail fundraising process approaching its deadline.

Ankur Sharma | 28 September 2026
Support

Hi! How can we help you today?

Loading…